Marco Tuccori

The REporting of A Disproportionality Analysis for DrUg Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance (READUS-PV): Explanation and Elaboration

Michele Fusaroli, Francesco Salvo, Bernard Bégaud et al. · Drug Safety · 2024 · 273 citations · Full text

Pharmacy, Pharmacology, Clinical Pharmacology +15

Pioglitazone use and risk of bladder cancer: population based cohort study

Marco Tuccori, Kristian B. Filion, Hui Yin et al. · BMJ · 2016 · 231 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +9

The Reporting of a Disproportionality Analysis for Drug Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance (READUS-PV): Development and Statement

Michele Fusaroli, Francesco Salvo, Bernard Bégaud et al. · Drug Safety · 2024 · 183 citations · Full text

Pharmacy, Pharmacology, Clinical Pharmacology +16

Anti-SARS-CoV-2 neutralizing monoclonal antibodies: clinical pipeline

Marco Tuccori, Sara Ferraro, Irma Convertino et al. · mAbs · 2020 · 162 citations · Full text

Pharmacy, Immunology, Infectious Diseases +17

Cyclophosphamide-methotrexate ‘metronomic’ chemotherapy for the palliative treatment of metastatic breast cancer. A comparative pharmacoeconomic evaluation

Guido Bocci, Marco Tuccori, Urban Emmenegger et al. · Annals of Oncology · 2005 · 108 citations · Full text

Medicine, Oncology, Pharmacoeconomics +14